FDAapproval54% confidence
Competitive Generic Therapy Approvals
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (melanoma) as MC1R-targeted therapy.
Regulatory Analysis
Explore the FDA’s Competitive Generic Therapy Approvals page, offering insights into the program designed to encourage generic drug competition. Access information about approved CGT products and find resources, including a downloadable CGT approvals spreadsheet.
Supporting Context
- Therapeutic area
- Oncology · Melanoma
- Sub-indication
- Melanoma
Related signal: Phase I/IIa Trial of MC1R-targeted Therapy with Nivolumab in Advanced Melanoma